JXR (01951) surged more than 3%, reaching HK$2.6 by the time of writing, with a trading volume of HK$45.40 million. The uptick follows recent policy developments favoring fertility support. On December 13, the National Healthcare Security Administration held a meeting in Beijing, emphasizing the need to align with national population strategies by enhancing maternity insurance and long-term care insurance. Key measures include improving coverage for prenatal medical expenses and aiming for zero out-of-pocket delivery costs under policy terms nationwide by 2025.

The meeting outlined that 31 provinces, autonomous regions, municipalities, and Xinjiang Production and Construction Corps will include eligible assisted reproductive treatments in medical insurance coverage, with seven provinces guaranteeing full coverage for delivery-related hospitalization costs. Additionally, 95% of regions will directly distribute maternity subsidies to insured individuals.

Earlier this month, JXR announced its board's approval to repurchase shares worth at least HK$100 million in the open market. According to the company's investor relations update, JXR repurchased 23.224 million shares last week, spending HK$57.717 million. So far this month, the company has bought back 30.946 million shares, totaling HK$77.515 million.

JXR reiterated its commitment to improving operational performance, driving intrinsic value growth, and delivering sustainable returns to shareholders.